Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report)'s stock price gapped up prior to trading on Monday. The stock had previously closed at $20.13, but opened at $21.12. Nuvectis Pharma shares last traded at $21.20, with a volume of 1,499 shares changing hands.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on the stock. Roth Capital raised their price objective on shares of Nuvectis Pharma from $20.00 to $33.00 and gave the company a "buy" rating in a report on Monday, July 6th. HC Wainwright reaffirmed a "buy" rating and set a $39.00 price objective on shares of Nuvectis Pharma in a research report on Thursday, September 24th. Weiss Ratings upgraded shares of Nuvectis Pharma from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, September 21st. Loop Capital set a $40.00 target price on Nuvectis Pharma in a report on Tuesday, September 1st. Finally, Cantor Fitzgerald started coverage on Nuvectis Pharma in a report on Monday, August 24th. They issued an "overweight" rating on the stock. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Nuvectis Pharma presently has a consensus rating of "Moderate Buy" and a consensus target price of $36.25.
View Our Latest Stock Report on Nuvectis Pharma
Nuvectis Pharma Price Performance
The firm has a 50 day moving average of $21.83 and a two-hundred day moving average of $16.16. The stock has a market cap of $664.22 million, a PE ratio of -15.54 and a beta of -0.24.
Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.04). As a group, equities analysts anticipate that Nuvectis Pharma, Inc. will post -1.01 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the stock. Bank of America Corp DE lifted its position in Nuvectis Pharma by 10.2% in the first quarter. Bank of America Corp DE now owns 14,847 shares of the company's stock valued at $115,000 after acquiring an additional 1,377 shares during the last quarter. Legal & General Group Plc acquired a new position in Nuvectis Pharma in the second quarter valued at $31,000. Avalon Trust Co acquired a new position in Nuvectis Pharma in the second quarter valued at $257,000. Deutsche Bank AG purchased a new position in shares of Nuvectis Pharma during the second quarter worth about $310,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Nuvectis Pharma during the second quarter worth about $676,000. Institutional investors and hedge funds own 96.77% of the company's stock.
About Nuvectis Pharma
(
Get Free Report)
Nuvectis Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with cancer and other serious unmet medical needs. The company's research and development programs are centered on novel small-molecule medicines designed to target biological pathways involved in tumor growth and treatment resistance.
Nuvectis' lead product candidate, NXP800, is an orally administered investigational inhibitor of the heat shock factor 1 pathway. It is being evaluated in clinical studies for advanced solid tumors, including ovarian cancer and other tumor types in which this pathway may play a role.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nuvectis Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvectis Pharma wasn't on the list.
While Nuvectis Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
